Wide Ranks

CVM

Cel-Sci Corporation

0.6110

Top Statistics
Market Cap 38 M Forward PE -1.27 Revenue Growth 0.00 %
Current Ratio 0.64 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.93 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 435781 Total Cash Per Share 0.0070 Total Debt 12 M
Total Debt To Equity 143.19 Current Ratio 0.64 Book Value Per Share 0.1560
All Measures
Short Ratio 1148.00 % Message Board Id finmb_258746 Shares Short Prior Month 4 M
Return On Equity -2.50 City Vienna Uuid ca5a217d-b481-3b5b-8c9f-61870f0a2da7
Previous Close 0.6160 First Trade Date Epoch Utc 439 M Book Value 0.1560
Beta 0.6880 Total Debt 12 M Volume 143028
Price To Book 3.92 Last Split Date 1 B Fifty Two Week Low 0.5400
Total Cash Per Share 0.0070 Shares Short Previous Month Date 1 B Target Median Price 7.00
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 7.73
Net Income To Common -29101132 Ask 0.6414 Short Percent Of Float 0.0793
Implied Shares Outstanding 63 M Last Fiscal Year End 1 B Trailing Peg Ratio None
Average Daily Volume10 Day 502850 Average Volume10days 502850 Total Cash 435781
Next Fiscal Year End 1 B Held Percent Insiders 0.0292 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 0.6160
Target Low Price 6.20 Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.8774
Open 0.6010 Free Cashflow -8456696 State VA
Dividend Yield 0.00 % Return On Assets -0.6140 Time Zone Short Name EST
Trailing Eps -0.5800 Day Low 0.6000 Address1 8229 Boone Boulevard
Shares Outstanding 63 M Price Hint 4 Target High Price 10.00
Website https://cel-sci.com 52 Week Change -0.7289 Average Volume 357287
Forward Eps -0.4400 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 7.90 % Last Split Factor 1:25 Regular Market Day High 0.6194
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 143.19
Fifty Two Week High 3.23 Day High 0.6194 Shares Short 4 M
Regular Market Open 0.6010 Industry Key biotechnology Bid 0.6160
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0772
Operating Cashflow -19039266 Currency USD Time Zone Full Name America/New_York
Market Cap 38 M Is_nasdaq_100 False Zip 22182
Quote Type EQUITY Industry Biotechnology Ex Dividend Date 841 M
Regular Market Day Low 0.6000 Held Percent Institutions 0.0999 Long Name CEL-SCI Corporation
Current Price 0.6110 Address2 Suite 802 Enterprise To Ebitda -1.93
Financial Currency USD Current Ratio 0.64 Industry Disp Biotechnology
Number Of Analyst Opinions 3 Country United States Float Shares 59 M
Two Hundred Day Average 1.33 Enterprise Value 49 M Forward PE -1.27
Regular Market Volume 143028 Ebitda -25523336 Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States.

The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer.

In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease.

CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.